BIOLOGY.DIGITAL
Recursion and Exscientia Enter Definitive $688M Agreement to Form End-to-End TechBio Leader

Image: BioSpace

Partnership

Recursion and Exscientia Enter Definitive $688M Agreement to Form End-to-End TechBio Leader

July 15, 2026 • Source: BioSpace

Recursion Pharmaceuticals and Exscientia announced a definitive agreement to combine in an all-stock transaction valued at $688 million, uniting high-content phenomic biology with precision automated chemistry.

**Executive Summary (2026-07-15):** Recursion Pharmaceuticals and Exscientia announced a definitive agreement to combine in an all-stock transaction valued at $688 million, uniting high-content phenomic biology with precision automated chemistry. Source: BioSpace.

Technical Architecture & R&D Impact

The combined entity pairs Recursion OS and the BioHive-2 supercomputer (60+ petabytes of proprietary phenomic and transcriptomic data) with Exscientia's active-learning medicinal chemistry design loops and automated synthesis studio. The combined clinical pipeline spans over 10 clinical and preclinical programs alongside more than $450 million in near-term milestone opportunities with Roche/Genentech, Sanofi, Bayer, and Merck KGaA.

Enterprise Biopharma Procurement Takeaways

For computational biology leads, medicinal chemists, and R&D IT architects, this milestone underscores the rapid convergence of wet-lab experimental validation and scalable cloud foundation models during H2 2026. Teams evaluating vendors in the Partnership category should benchmark API reproducibility, GxP audit readiness, and zero-data-retention VPC deployment terms.

Related Products

Published July 15, 2026

More News

Last updated: July 15, 2026

Ask AI